COVID-19 is the disease caused by SARS-CoV-2 that portends both a relatively high mortality rate as well as high rate of intensive care admission amongst all age groups; however effective therapy remains poorly characterized. Post-transplant patients are especially high risk and underrepresented in the literature. In these patients, cytokine release may play a significant role in the development of acute respiratory distress syndrome, raising the hypothesis that interleukin-6 inhibitors such as tocilizumab may be of benefit. Here, we describe two high-risk post-transplant patients who were treated with single-dose tocilizumab after intubation for moderate acute respiratory distress syndrome secondary to confirmed COVID-19 infection. Both patients recovered rapidly and were successfully extubated and discharged from the hospital without need for supplemental oxygen shortly thereafter, and their clinical improvement correlated with response in interleukin-6 levels. Tocilizumab appears to hold promise for critically ill COVID-19 patients who require mechanical ventilation when given shortly after intubation.
【저자키워드】 COVID-19, Critical care, Respiratory failure, acute respiratory distress syndrome, Tocilizumab, LIST, ARDS, acute respiratory distress syndrome, COVID-19, coronavirus disease of 2019, CT, computerized tomography, IL, interleukin, CAR-T cell: chimeric antigen receptor T-cell, 【초록키워드】 SARS-CoV-2, intensive care, mechanical ventilation, hospital, interleukin-6, intubation, Critically ill, Patient, Clinical improvement, age, inhibitor, Admission, moderate, patients, acute respiratory distress, Hypothesis, COVID-19 patient, high risk, supplemental oxygen, syndrome, effective therapy, Confirmed COVID-19 infection, cytokine release, high mortality rate, benefit, caused, the disease, characterized, treated, appear, correlated, discharged, raising, 【제목키워드】 acute respiratory distress, syndrome, case sery, patients with COVID-19,